Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
Industry: Healthcare

OFF LIST - 660 consecutive market days: OFF LIST as of 10/18/2013 Through 11/14/2016

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ARO-ANG3 to treat hypertriglyceridemia; ARO-Lung1 for the treatment of an undisclosed pulmonary target; ARO-HIF2 to treat renal cell carcinoma; ARO-F12 for hereditary angioedema and thromboembolic disorders; and ARO-AMG1 for the treatment of an undisclosed genetically validated cardiovascular target. Arrowhead Pharmaceuticals, Inc. has collaboration and license agreement with Amgen, Inc.; and with Janssen Pharmaceuticals, Inc. The company was formerly known as Arrowhead Research Corporation and changed its name to Arrowhead Pharmaceuticals, Inc. in April 2016. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Current Quote*
Last: $12.950
Change: -0.580
Book: $11.906
Volume: 1,673,576

As Of: 10/19 16:07 ET
*Quotes delayed by 20min.

Graphs for ARWR


3 Month Graph


6 Month Graph


1 Year Graph